VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-5.2%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$824M
AUM Growth
+$824M
(-11%)
Cap. Flow
+$30.2M
Cap. Flow
% of AUM
3.67%
Top 10 Holdings %
Top 10 Hldgs %
67.68%
Holding
37
New
9
Increased
2
Reduced
6
Closed
8
Top Buys
| 1 |
LENZ
LENZ Therapeutics
LENZ
|
$49.6M |
| 2 |
GH Research
GHRS
|
$27.7M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
$25M |
| 4 |
PRVB
Provention Bio, Inc. Common Stock
PRVB
|
$24.5M |
| 5 |
CVRx
CVRX
|
$17.7M |
Top Sells
| 1 |
CNST
Constellation Pharmaceuticals, Inc.
CNST
|
$94M |
| 2 |
TRIL
Trillium Therapeutics Inc.
TRIL
|
$19.8M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$13.2M |
| 4 |
APTO
Aptose Biosciences, Inc.
APTO
|
$9.59M |
| 5 |
Adicet Bio
ACET
|
$8.4M |
Sector Composition
| 1 | Healthcare | 91.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Instil Bio
TIL
$182M
| $133M | 16.09% | 6,865,076 | – | – |
|
2
Aclaris Therapeutics
ACRS
$209M
| $80.1M | 9.72% | 4,563,962 +843,380 | +23% | +$14.8M |
|
3
VistaGen Therapeutics
VTGN
$102M
| $50.5M | 6.13% | 16,047,286 -255,310 | -2% | -$804K |
|
|
LENZ
4
LENZ Therapeutics
LENZ
$1.1B
| $49.6M | 6.01% | +1,612,617 | New | +$49.6M |
|
|
MRNS
5
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $47.4M | 5.75% | 2,641,809 | – | – |
|
6
Relmada Therapeutics
RLMD
$37.2M
| $44.4M | 5.39% | 1,387,720 +534,514 | +63% | +$17.1M |
|
7
Olema Pharmaceuticals
OLMA
$375M
| $43M | 5.21% | 1,536,193 | – | – |
|
8
Celldex Therapeutics
CLDX
$1.47B
| $41.5M | 5.03% | 1,240,610 | – | – |
|
9
Altimmune
ALT
$338M
| $34.5M | 4.18% | 3,500,000 | – | – |
|
|
KNTE
10
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $34.3M | 4.16% | 1,473,014 | – | – |
|
|
11
GH Research
GHRS
$837M
| $27.7M | 3.36% | +1,275,831 | New | +$27.7M |
|
12
Cullinan Oncology
CGEM
$445M
| $25.1M | 3.05% | 976,145 -200,000 | -17% | -$5.15M |
|
|
CNTA
13
Centessa Pharmaceuticals
CNTA
$2.25B
| $25M | 3.04% | +1,127,272 | New | +$25M |
|
|
PRVB
14
DELISTED
Provention Bio, Inc. Common Stock
PRVB
| $24.5M | 2.97% | +2,902,744 | New | +$24.5M |
|
|
TRIL
15
DELISTED
Trillium Therapeutics Inc.
TRIL
| $19.4M | 2.36% | 2,001,686 -2,038,314 | -50% | -$19.8M |
|
16
ESSA Pharma
EPIX
$11.4M
| $17.9M | 2.17% | 625,754 | – | – |
|
|
17
CVRx
CVRX
$205M
| $17.7M | 2.15% | +633,370 | New | +$17.7M |
|
18
Pharvaris
PHVS
$1.39B
| $16.8M | 2.04% | 902,882 | – | – |
|
19
Athira Pharma
ATHA
$15.3M
| $15.2M | 1.84% | 1,485,005 -206,618 | -12% | -$2.12M |
|
20
RAPT Therapeutics
RAPT
$188M
| $12.4M | 1.51% | +391,000 | New | +$12.4M |
|
21
Kura Oncology
KURA
$686M
| $12M | 1.45% | 575,000 | – | – |
|
22
Keros Therapeutics
KROS
$618M
| $11.6M | 1.4% | 272,306 -100,000 | -27% | -$4.25M |
|
23
Cogent Biosciences
COGT
$1.69B
| $8.83M | 1.07% | 1,088,817 | – | – |
|
24
Aligos Therapeutics
ALGS
$73.3M
| $8.33M | 1.01% | 408,377 | – | – |
|
|
AKYA
25
DELISTED
Akoya BioSciences
AKYA
| $7.74M | 0.94% | +400,000 | New | +$7.74M |
|